Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

被引：57

作者：

Demetri, GD

van Oosterom, AT

Blackstein, M

Garrett, C

Shah, M

Heinrich, M

McArthur, G

Judson, I

Baum, CM

Casali, PG

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] UZ Gasthuisberg, Louvain, Belgium

[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada

[4] Univ Toronto, Toronto, ON, Canada

[5] H Lee Moffit Canc Ctr & Res Inst, Tampa, FL USA

[6] Ohio State Univ, Columbus, OH 43210 USA

[7] Oregon Hlth Sci Univ, Ctr Canc, Portland, OR 97201 USA

[8] Portland VA Med Ctr, Portland, OR USA

[9] PeterMacCallum Canc Ctr, Melbourne, Australia

[10] Royal Marsden Hosp, Sutton, Surrey, England

[11] Pfizer Inc, La Jolla, CA USA

[12] Inst Nazl Tumori, Milan, Italy

来源：

关键词：

D O I：

10.1200/jco.2005.23.16_suppl.4000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：308S / 308S

页数：1